Teri L. Lawver

EVP Chief Commercial Officer, Dexcom.

Companies

Celldex TherapeuticsSVP & Chief Commercial Officer Nov 12, 2025 to now¹
Altimmune, Inc.Board member Feb 26, 2025 to now²
DexcomEVP Chief Commercial Officer Jan 9, 2023 to Mar 14, 2024³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Dexcom DXCM66,641 shares⁴$5.7M at $86.09Mar 12, 2024

As of each latest filing. The line shows shares held over time.

Recent filings

Mar 12, 2024Sold 4,764 shares at $134.41 of Dexcom⁴
Mar 8, 2024Granted 26,053 shares of Dexcom⁵
Mar 8, 2023Granted 45,352 shares of Dexcom⁶

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARCelldex Therapeutics, SVP & Chief Commercial Officer
2
SEC EDGARAltimmune, Inc., Board member
3
SEC EDGARDexcom, EVP Chief Commercial Officer
4
SEC EDGARDexcom shares after the filing of Mar 12, 2024
5
SEC EDGARForm 4 filed Mar 11, 2024
6
SEC EDGARForm 4 filed Mar 10, 2023